TD Cowen Raises Natera (NTRA) Price Target to $480

TD Cowen has reiterated its Buy rating for Natera, Inc. with a raised price target of $480 on October 13, 2026, a 21.52% upside from the current price.

By EarningsIQ Research Desk · Published Oct 16, 2026, 2:07 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

TD Cowen raised its price target on Natera, Inc. ($NTRA) to $480 from $340 on October 13, 2026, and rates the stock "Buy".

Since the rating, $NTRA is down 0.6% to date (from the $395.65 close on Oct 13, 2026).

NTRA Natera, Inc.

$393.44 +71.93% year to date

Daily close · Oct 16, 2026

Key Points

On October 13, 2026, TD Cowen reiterated its Buy rating on Natera, Inc. with a new price target of $480, up from $340.
TD Cowen's $480 price target implies 21.52% upside from Natera, Inc.'s ($NTRA) current $394.99 share price.
As of October 16, 2026, Natera shares traded recently around $394.99, which is about 17.7% below the analyst's target.
Natera reported a revenue of approximately $2.71 billion for the trailing twelve months, reflecting a year-over-year growth of 37.7%.

Get $NTRA trade alerts by text

We text you when insiders, Congress or big funds trade $NTRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures

TD Cowen has reiterated its Buy rating for Natera, Inc. (NasdaqGS: NTRA) on October 13, 2026, raising its price target to $480 from a previous target of $340. This marks a significant adjustment in their outlook for the healthcare diagnostics company, which specializes in molecular testing services.

TD Cowen's Call on Natera

TD Cowen's new price target of $480 represents a strong bullish stance on Natera, suggesting confidence in the company's growth prospects. The firm is optimistic about Natera's future performance, especially given its recent revenue growth of 37.7% year-over-year. As of October 16, 2026, Natera's shares were recently trading around $394.99, which is about 17.7% below the newly set target.

Other Institutional Activity in Natera

In addition to TD Cowen, several other institutional investors have shown interest in Natera. JPMorgan Chase & Co. reduced its holdings by 520,718 shares, leaving it with 12,865,346 shares valued at approximately $5.06 billion. BlackRock Inc. increased its stake by 237,042 shares, bringing its total to 10,914,608 shares worth about $4.29 billion. Meanwhile, Price (T. Rowe) Associates Inc. decreased its holdings by 3,163,268 shares, now holding 9,021,895 shares valued at about $3.55 billion. Vanguard Capital Management LLC added 219,904 shares, increasing its total to 6,228,216 shares worth around $2.45 billion.

Natera, Inc. Stock Down 2.4%

Natera's stock is currently trading around $394.99, which is below its new analyst target of $480. This recent price places the stock in a position where it could see upward movement if it meets growth expectations outlined by analysts. The shares have shown resilience, but the current trading level indicates potential upside if the company continues its strong revenue growth.

12-month forecast

$NTRA price target

Natera, Inc. daily closes and this analyst's $480 target. Not advice.

Recent Earnings

Natera reported a trailing twelve-month revenue of approximately $2.71 billion, with a net margin of -7.1%. The company is set to announce its next earnings report on November 5, 2026, which could provide further insights into its financial health and growth trajectory.

About Natera

Natera, Inc. is a diagnostics company headquartered in Austin, Texas, focused on developing and commercializing molecular testing services globally. Its offerings include personalized blood tests for cancer monitoring and hereditary cancer screening, positioning it as a key player in the healthcare diagnostics sector.

Bottom Line

Investors will be watching closely for Natera's upcoming earnings report on November 5, 2026, as it may influence future analyst ratings and price targets. TD Cowen's reiteration of its Buy rating suggests confidence in Natera's growth potential despite recent trading levels being below the newly set target.